Search research articles
Contact Us
Filters
Showing results (41-50 of 118) with videos related to
Page
of 12
Sort By:
The Oncologist
|
April 21, 2017
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy
Yang-Min Ning, Daniel Suzman, V Ellen Maher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments
Suparna B Wedam, Julia A Beaver, Laleh Amiri-Kordestani, et al.
Current Oncology Reports
|
August 28, 2020
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy
Sirisha L Mushti, Flora Mulkey, Shenghui Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer
Oladimeji Akinboro, Nicole Drezner, Anup Amatya, et al.
JCO Clinical Cancer Informatics
|
July 23, 2021
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Jeremy Mason, Yutao Gong, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Sorafenib for the treatment of advanced renal cell carcinoma
Robert C Kane, Ann T Farrell, Haleh Saber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Jaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
European Urology
|
June 4, 2023
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
Daniel Lee, Haley Gittleman, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
The Lancet. Oncology
|
October 17, 2021
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Tatiana M Prowell, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 118) with videos related to
Sort By:
Page
of 12
The Oncologist
|
April 21, 2017
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy
Yang-Min Ning, Daniel Suzman, V Ellen Maher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments
Suparna B Wedam, Julia A Beaver, Laleh Amiri-Kordestani, et al.
Current Oncology Reports
|
August 28, 2020
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy
Sirisha L Mushti, Flora Mulkey, Shenghui Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer
Oladimeji Akinboro, Nicole Drezner, Anup Amatya, et al.
JCO Clinical Cancer Informatics
|
July 23, 2021
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Jeremy Mason, Yutao Gong, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2006
Sorafenib for the treatment of advanced renal cell carcinoma
Robert C Kane, Ann T Farrell, Haleh Saber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 14, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Jaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
European Urology
|
June 4, 2023
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma
Daniel Lee, Haley Gittleman, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
The Lancet. Oncology
|
October 17, 2021
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Tatiana M Prowell, et al.
Page
of 12